Tirzepatide is a 39 amino acid synthetic peptide that activates both the GIP and the GLP-1 receptor. Its most quoted pharmacokinetic number is its elimination half-life, reported as approximately 5 days in the FDA prescribing information for tirzepatide (Mounjaro, Eli Lilly). That one figure explains most of what people observe about the molecule: plasma levels keep climbing for about the first month of once weekly administration, and the compound remains measurable for several weeks after administration stops. This page covers measurement and pharmacokinetics only. It is education, not medical advice.
What a 5 Day Half-Life Means in Practice
Half-life is the time required for a quantity to fall to half its starting value. It describes exponential decay, which means the fraction removed per unit of time stays constant while the absolute amount removed keeps shrinking. After one half-life roughly 50 percent remains, after two roughly 25 percent, after three roughly 12.5 percent. The curve flattens but never truly reaches zero, so practical questions about clearance are always questions about a threshold, not about a true endpoint. If the arithmetic is new to you, the general walkthrough in how to read a peptide half-life covers it step by step.
Applied to a 5 day half-life, the numbers after a single administration look like this:
| Half-lives elapsed | Days after administration | Approximate percent remaining |
|---|---|---|
| 0 | 0 | 100% |
| 1 | 5 | 50% |
| 2 | 10 | 25% |
| 3 | 15 | 12.5% |
| 4 | 20 | 6.3% |
| 5 | 25 | 3.1% |
| 6 | 30 | 1.6% |
You can reproduce this table, change the half-life figure, and read off any intermediate day with the peptide half-life decay calculator. Entering 5 days and a starting value of 100 percent produces the same curve, and entering 7 days produces the semaglutide comparison discussed further down.
One caution before reading too much into the table. A half-life is a population average derived from blood sampling in clinical studies. Individual clearance varies, and the amount of peptide circulating is not the same thing as the size of a biological effect. Concentration and response follow different curves.
Why Tirzepatide Lasts So Long: the C20 Fatty Diacid
Native GIP and GLP-1 are cleared from plasma in minutes. They are short peptides, they are cut rapidly by the enzyme dipeptidyl peptidase 4 (DPP-4), and they are small enough to be filtered by the kidney. A molecule built from that starting point needs structural changes before it can persist for days.
Tirzepatide carries two kinds of modification. First, amino acid substitutions near the N-terminus make the backbone resistant to DPP-4 cleavage. Second, and more importantly for the half-life, a C20 fatty diacid is attached through a linker to the lysine residue at position 20. This design was described in the published discovery paper for the molecule by Coskun and colleagues in Molecular Metabolism (2018), which reported the dual receptor pharmacology and the acylation strategy.
A fatty diacid is a long chain carboxylic acid with an acid group at both ends. The chain binds reversibly to serum albumin, the most abundant protein in plasma. The consequences are direct and measurable. The FDA prescribing information reports that tirzepatide is about 99 percent bound to plasma protein, with an apparent volume of distribution of roughly 10.3 L, close to plasma volume, and an apparent clearance of about 0.061 L per hour. A molecule travelling bound to albumin is too large to pass the glomerular filter, so renal loss is minimal, and the albumin pool acts as a slow release reservoir that hands the peptide back to the free fraction gradually.
Elimination then happens by metabolism rather than by excretion of the intact peptide. The label describes proteolytic cleavage of the peptide backbone, beta oxidation of the C20 diacid chain, and amide hydrolysis, with the resulting metabolites appearing in urine and faeces. Unchanged tirzepatide is not recovered in either. The same albumin binding trick, with chain length and linker varying, is used across several long acting peptides, as the comparison on the peptide half-life chart shows.
Absorption Also Shapes the Observed Curve
Half-life is often discussed as if it were purely an elimination property, but the measured terminal half-life of a subcutaneous peptide also reflects how slowly it leaves the injection site. The FDA prescribing information reports a median time to maximum plasma concentration of 8 to 72 hours after subcutaneous administration and absolute bioavailability of about 80 percent. A peak that can arrive anywhere from one third of a day to three days later is a slow absorption process by any standard.
When absorption is slower than elimination, the apparent half-life is partly governed by the absorption step. Pharmacologists call this flip flop kinetics. The practical consequence is that the published 5 day figure is specific to subcutaneous administration and should not be assumed to describe the intrinsic clearance of the molecule from blood.
Washout: How Long Until It Is Effectively Gone
The common rule of thumb is that a compound is essentially cleared after about 5 half-lives, at which point roughly 3 percent of the original amount remains. For tirzepatide that gives approximately 25 days after a single administration, or a little over three and a half weeks. Seven half-lives, about 35 days, leaves under 1 percent.
Two refinements matter. The rule applies to a single administration. After repeated weekly administration the body carries an accumulated amount, so the washout clock starts from a higher value and the practical interval is somewhat longer. And a threshold of 3 percent is a convention, not a biological boundary. Modern analytical assays can detect concentrations far below that level, so the answer to the question of how long it is detectable depends entirely on the sensitivity of the method used.
Steady State: Why Levels Climb for About Four Weeks
Accumulation happens whenever a new administration arrives before the previous one has cleared. With a 5 day half-life and a 7 day interval, each week spans about 1.4 half-lives, so roughly 38 percent of the previous week's amount is still present when the next one arrives. Levels therefore rise week by week until the amount cleared in a week equals the amount arriving, which is the definition of steady state.
The arithmetic of a 5 day half-life and a 7 day interval predicts an accumulation ratio of about 1.6 fold between the first week and the plateau. The FDA prescribing information states that steady state plasma concentrations are reached after 4 weeks of once weekly administration, which is consistent with that geometry: four weeks is roughly five and a half half-lives, enough for the accumulation series to converge. This article does not describe how amounts are escalated over time, which is a separate topic covered elsewhere on the site.
Tirzepatide Compared With Semaglutide
Semaglutide uses the same albumin binding strategy with a shorter C18 fatty diacid chain, and its FDA prescribing information reports an elimination half-life of approximately 1 week. Both compounds are therefore suited to once weekly administration, but their decay curves separate noticeably over a month.
| Property | Tirzepatide | Semaglutide |
|---|---|---|
| Reported elimination half-life | About 5 days (FDA prescribing information) | About 1 week (FDA prescribing information) |
| Acylation | C20 fatty diacid | C18 fatty diacid |
| Plasma protein binding | About 99% | Greater than 99% |
| Amount remaining at day 14 | About 14% | 25% |
| Amount remaining at day 28 | About 2% | 6.3% |
| Approximate 5 half-life washout | About 25 days | About 35 days |
| Time to steady state (label) | About 4 weeks | About 4 to 5 weeks |
Plotted together, the two curves start at the same point and diverge steadily. By one month the semaglutide curve sits roughly three times higher than the tirzepatide curve as a fraction of the starting amount, purely because of the two day difference in half-life. This is the compounding behaviour of exponential decay: small differences in the half-life produce large differences in the tail. Model both on the decay calculator to see the gap open up, and read what affects peptide half-life for the structural factors behind figures like these.
What These Numbers Do Not Tell You
Every figure quoted here is a population average from label pharmacokinetic sections. Real clearance varies with body weight, renal and hepatic function, and other factors, and individual values sit on a distribution around the published mean. Half-life also says nothing about potency, receptor occupancy, or duration of any biological effect, which are separate measurements entirely.
Finally, half-life is a property of the molecule in the body, not of the vial. Questions about milligrams, concentration and syringe units are handled separately by the tirzepatide unit calculator.
PeptideCalc publishes calculators and explainers for research and education only. Pharmacokinetic figures on this page are drawn from publicly available FDA prescribing information and named published literature. Nothing here is medical advice, a recommendation, or guidance on use of any compound. Research peptides are not for human consumption outside of an approved clinical setting.